Clinical Trials Sponsored by Lymphoma Study Association

Total 131 results

Lymphoma Study Association

Completed

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

United States, Australia, Belgium, Czechia, Finland, Germany, Israel, Sweden, Switzerland, United Kingdom
Lymphoma Study Association

Completed

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

France
Lymphoma Study Association

Completed

Mini-CHOP and Rituximab in Patients Aged Over 80 Years

Diffuse Large B-Cell Lymphoma
Lymphoma Study Association

Completed

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Lymphoma

France, Belgium
Lymphoma Study Association

Completed

Randomized Study for Patients With Follicular Lymphoma Needing Treatment

Follicular Lymphoma

France, Belgium
Lymphoma Study Association

Terminated

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

Mantle Cell Lymphoma
Lymphoma Study Association

Completed

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Lymphoma Study Association

Completed

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

B-Cell Lymphoma

France, Belgium, Switzerland
Lymphoma Study Association

Terminated

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

CD20-Positive Large B-Cell Lymphoma

France
Lymphoma Study Association

Completed

Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

Lymphoma, Non-Hodgkin | Diffuse Large B-cell Lymphoma

Belgium, France
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
Lymphoma Study Association

Completed

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

France, Italy
Lymphoma Study Association
Amgen

Terminated

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
BeiGene
Lymphoma Study Association

Active, not recruiting

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (TIRHOL)

Classical Hodgkin Lymphoma

United States, Australia, France, Belgium, Puerto Rico
Lymphoma Study Association
Amgen

Completed

R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Lymphoma Study Association
Amgen

Completed

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Untreated CD20-positive Large B-cell Lymphoma

France
Lymphoma Study Association
Bayer

Completed

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma (ZBEAM2)

Lymphoma, Large Cell, Diffuse

France
Lymphoma Study Association
Amgen

Completed

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Diffuse Large-Cell Lymphoma

France, Belgium
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
Lymphoma Study Association
Fondation ARC

Completed

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Belgium
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
European Mantle Cell Lymphoma Network
Lymphoma Study Association; German Low Grade Lymphoma Study Group

Unknown

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Lymphoma, Mantle-Cell

France, Germany, Poland
Lymphoma Study Association
Hoffmann-La Roche

Completed

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Untreated T-cell Angioimmunoblastic Lymphoma

France
Lymphoma Study Association
Janssen-Cilag International NV

Completed

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

France, Belgium
French Innovative Leukemia Organisation
Lymphoma Study Association

Completed

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Mantle Cell Lymphoma

France
Lymphoma Study Association

Unknown

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, France
European Mantle Cell Lymphoma Network
Nordic Lymphoma Group; HOVON - Dutch Haemato-Oncology Association; Lymphoma Study... and other collaborators

Unknown

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (MCLelderly)

Lymphoma, Mantle-Cell

Czech Republic, Denmark, France, Germany, Italy, Netherlands, Poland
Lymphoma Study Association
Janssen-Cilag International NV

Terminated

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Follicular Lymphoma

France, Belgium
Centre Hospitalier Universitaire Dijon
The Lymphoma Study Association

Completed

Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL (AHL 2011)

Hodgkin's Lymphoma

France, Belgium
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia
Czech Lymphoma Study Group

Not yet recruiting

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Lymphoma, T-Cell, Peripheral

Czechia
Czech Lymphoma Study Group

Recruiting

Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)

Non Hodgkin Lymphoma (NHL)

Czechia
Czech Lymphoma Study Group

Unknown

CNS Prophylaxis in Diffuse Large B-cell Lymphoma (CLSG-CNS-001)

Diffuse Large B-cell Lymphoma

Czech Republic
Lymphoma Study Association
Institute of Cancer Research, United Kingdom; Australasian Leukaemia and Lymphoma... and other collaborators

Completed

Primary Rituximab and Maintenance

Follicular Lymphoma

France, Thailand, Belgium, Spain, Argentina, Australia, Brazil, Colombia, Denmark, Netherlands, New Zealand, Peru
French Study Group on Chronic Lymphoid Leukemia
French Innovative Leukemia Organisation; Lymphoma Study Association; Département...

Completed

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Lymphoplasmacytic Lymphoma

France
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ)

Splenic Marginal Zone Lymphoma

Spain, Denmark, France, Norway, Switzerland, Sweden, Italy
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role (PIMENTO)

Marginal Zone Lymphoma

France, Italy, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary Central Nervous System Lymphoma

Denmark, Finland, Italy, Israel, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Primary Mediastinal B-cell Lymphoma

Norway, United Kingdom, Italy, Switzerland, Czechia, United States, China, Argentina, Canada, Germany, Poland, Portugal, Sweden, Ukraine
International Extranodal Lymphoma Study Group (IELSG)

Completed

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Central Nervous System Lymphoma

Germany, Italy, United Kingdom, Switzerland
German Low Grade Lymphoma Study Group

Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

Indolent Lymphoma

Germany
International Extranodal Lymphoma Study Group (IELSG)

Withdrawn

A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Lymphoma, B Cell
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Terminated

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Lymphoma, B-Cell

Italy
The Thai Lymphoma Study Group
Takeda

Completed

B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

Thailand
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

Marginal Zone Lymphoma

Italy, Switzerland, Austria
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)

Splenic Marginal Zone Lymphoma | Marginal Zone Lymphoma | Nodal Marginal Zone Lymphoma

France, Switzerland, Italy, Belgium, Portugal
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Spain, Italy, Austria
International Extranodal Lymphoma Study Group (IELSG)

Completed

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

Marginal Zone B-cell Lymphoma

Italy, France
International Extranodal Lymphoma Study Group (IELSG)

Terminated

This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas (IELSG33)

Diffuse Large B-Cell Lymphoma of the Breast

Clinical Trials Sponsored by Lymphoma Study Association

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations